CTAP

This highly potent and selective μ opioid receptor antagonist exhibits an IC50 of 3.5 nM with over 1200-fold selectivity for δ opioid and somatostatin receptors. Its brain-penetrant properties make it a valuable pharmacological tool for in vivo studies of pain, addiction, and reward pathways, as well as for in vitro receptor characterization.